This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
physician groups representing radiation oncology have partnered to try to reform Medicare payments and expand patient access to high-quality care. In other news, ASTRO said that chief executive officer Laura Thevenot plans to retire at the end of 2024 after leading the organization since 2002.
milla1cf Fri, 06/21/2024 - 20:25 June 21, 2024 — The American Society for Radiation Oncology ( ASTRO ) announced today that following a nationwide search, Vivek S. Dr. Kavadi will succeed Laura Thevenot, who previously announced her intent to retire after leading the organization since 2002.
The American Society for Radiation Oncology (ASTRO) has appointed Texas radiation oncologist Vivek Kavadi, MD, as its new CEO. Kavadi plans to leave his current role as chief radiation oncology officer for the US Oncology Network to lead ASTRO, where he has been a member and served in various roles since 1994.
The American College of Radiology (ACR), which collaborated with radiologic technologist (RT) societies to create the Registered Radiologic Assistant Position (RRA) in 2002, has remained neutral on the bill and noted that it continues to be opposed to nonphysician providers (NPPs) performing imaging supervision or interpretation.
milla1cf Tue, 01/09/2024 - 11:02 January 9, 2024 — The American Society for Radiation Oncology ( ASTRO ) announced that CEO Laura Thevenot plans to retire at the end of 2024 after leading the organization since 2002. Additionally, the association’s professional staff expanded from 18 in 2002 to more than 80 currently. “It
As associate medical director of the CT Clinical Innovation Center in Mayo Clinic Rochester’s department of radiology, he supports the mission of facilitating high-impact imaging innovations with direct effect on patients, such as radiation dose reduction techniques, novel CT technologies, and quantitative assessment of disease activity.
He was an honorary lecturer at ECR 2002 and was awarded ESR honorary membership in 2010. Kalender's other main fields of research were radiation protection and the development of quantitative diagnostic procedures, for example, for the assessment of osteoporosis, lung, and cardiac diseases, noted the International Society for CT.
Harris in his editorial, however, cited randomized controlled trials that influenced the task force’s recommendations in 2002 and 2009 that showed little to no statistically significant reduction in breast cancer mortality in women ages 40 to 49 years. He also wrote that overdiagnosis can be harmful to women.
The decision marks a return of sorts to the task force's 2002 breast cancer screening recommendations, in which the UPSTF recommended that women receive annual or biennial screening beginning at 40. Furthermore, these women should also begin annual mammography at ages 25 to 40.
Marcinkiewicz and colleagues conducted a study that included 24,401 participants in the NLST who underwent low-dose CT between August 2002 and September 2007. Follow-up of these patients continued through December 2015. All-cause mortality was assessed at two-year and 10-year follow-up from baseline imaging.
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content